Thursday, September 26, 2024 - Day Three of Main Conference - EST/EDT (Eastern Daylight, GMT-4)
Thursday, September 26, 2024 - Day Three of Main Conference - EST/EDT (Eastern Daylight, GMT-4)
- Johan Rockberg - Professor, KTH Royal Institute of Technology
- James Zawada - Associate Director Process Science, Sutro Biopharma
How it will work is we have 3 Round Tables each covering a different challenge of Upstream & Cell Culture in Bioprocessing. Each will be led by an expert. The expert will kick off and guide the discussion which will last for 30 minutes. At the end of the 30 minutes the leader will report their main conclusions to the room for a maximum of 10 minutes.
Roundtable Discussions
Cell Culture Optimization
- Cell Line Development: Selecting and developing an optimal cell line is crucial for achieving high product yields and quality. Identifying a cell line with desirable characteristics, such as growth rate, productivity, and stability, can be a time-consuming and complex process.
- Cultivation Conditions: Maintaining optimal conditions for cell growth and productivity is challenging. Factors like temperature, pH, nutrient availability, and gas exchange need to be carefully controlled to ensure optimal performance. Achieving consistent and reproducible results across large-scale bioreactors adds another layer of complexity
Bioreactor & Upstream Scale-Up:
- Transition from Lab Scale to Production Scale: Scaling up bioprocesses from small laboratory bioreactors to large-scale production facilities can lead to challenges in maintaining consistent conditions. Factors like mixing, mass transfer, and heat dissipation become more complex as the scale increases. Achieving uniform distribution of nutrients and gases becomes crucial for maintaining cell health and product quality. Take into account Perfusion versus Fed-Batch.
- Bioreactor Design: The design of bioreactors for large-scale production must consider factors such as hydrodynamics, shear stress, and heat transfer to ensure optimal cell growth and product formation. Choosing the right type of bioreactor and ensuring scalability without compromising performance is a significant challenge
Process Monitoring and Control:
- Real-time Monitoring: Continuous monitoring of various parameters, such as cell viability, metabolite concentrations, and product titer, is essential for process control and optimization. Implementing reliable real-time monitoring techniques can be challenging, particularly for complex bioprocesses.
- Process Control: Maintaining tight control over the bioprocess is crucial to achieve consistent product quality. Controlling variables such as pH, dissolved oxygen, and nutrient concentrations requires advanced control strategies. Deviations from optimal conditions can negatively impact cell growth, viability, and product quality
- Swetha Kumar - Scientist, Sanofi
- Jianfa Ou - Principal Scientist, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb
- Lara E. Krebs - Advisor - Bioprocess Research and Development, Eli Lilly and Company
- Tingting Cui, Ph.D. - Associate Principal Scientist, AstraZeneca
- Qian Ruan, Ph.D - Senior Vice president of TechOps and Supply Chain, Arcturus Therapeutics
- What do we see as standards and regulatory science needs to increase adoption of advanced technologies?
- How can AI be incorporated into smart and advanced manufacturing?
- How can regulatory agencies and industry work together to make safe and smart manufacturing a reality?
- James Coburn - Advanced Manufacturing Team Lead, Senior Advisor for Emerging Technologies, FDA
- Qian Ruan, Ph.D - Senior Vice president of TechOps and Supply Chain, Arcturus Therapeutics
- Nadine Ritter, Ph.D. - President and Analytical Advisor, Global Biotech Experts, LLC
Dark Horse Consulting Representative
- Li Jing - Senior Manager, US Pharmacopeia
- Greg Adams - Senior Director, Global Analytical Strategy & Development, FUJIFILM Diosynth Biotechnologies
- Vamsikrishna Kandhi - Principal Scientist, Pfizer
- Unpacking the current barriers to RNA gene therapy use
- Advancements in the processing of RNA to improve outcomes (remove unwanted cells, viral concentration, purification)
- Scalable processes
- Approaches to reaching high yield downstream purification
- Removing aggregates and contaminates from your titer
- Removal of partially-full capsids from your full-capsid yield
- Seema Bhatlekar - Scientist, Johnson & Johnson Innovative Medicine
- Shashi Murthy, PhD - CTO and Co-Founder, Nanite Inc.
- Tailored design and engineering of polymeric nanoparticles for optimal cell interaction, targeting, and therapeutic delivery.
- Diverse delivery strategies and tissue targeting approaches for specific disease applications
- Effective encapsulation techniques to preserve cell viability, functionality, and differentiation potential during delivery
- Case study: how are these being explored/used
Cell-based manufacturing of gene therapy molecules presents multiple challenges in maintaining high product yield and quality. Traditionally, isolating the desired DNA molecules is challenging. Additionally, cell-based approaches require long manufacturing timelines. To address these speed and quality challenges, we developed an enzymatic method capable of producing DNA drug substance at g/L scale and with >99% purity using chromatographic methods. This cell-free process has enabled highly accelerated production timelines compared to cell-based methods and the enzymatic platform facilitates diverse production application with constructs up to at least 7000bp in size.
- Anthony Dawson - Senior Scientist, Generation Bio
- Duncan McVey, Ph.D. - Associate Director, Bristol-Myers Squibb
- Hyo-Young Jeong,PhD - Senior Scientist, Process Cell Sciences, Merck & Co Inc.
- Yuan Yuan - Sr Scientist, Cell Culture Development, Teva Pharmaceuticals
- Yingxue Zhang - Scientist, Upstream Process Development, Jecho Labs
- Jason Souvaliotis - Associate Scientist, Biopharmaceutical Drug Substance Process Development, GSK
- Vivek Kumar Muthusamy - Process Development Senior Scientist, Amgen
In the slowly evolving landscape of bioprocess development and manufacturing, digital bioprocess-twins have emerged as potential accelerators. While advanced algorithms are at the heart of this endeavor, they are just one piece of the puzzle. The talk delves into key discussion points that are integral to this paradigm shift. The foundation of accelerated process development and automated process control starts with a clever experimental design, in-time data accessibility combined with powerful modeling algorithms. The talk will highlight the advantages of using hybrid modeling, while emphasizing the other critical aspects of his journey. Several industrial relevant upstream showcases for microbial and mammalian cell lines will be highlighted. Thereby, concepts to save experimental effort by up to 70% will be elaborated, and the modeling structure created in the late-stage development will be reused for real-time monitoring and control in the later stages. Additionally, a downstream optimization showcase for UF/DF/SPTFF will be highlighted.
- Mark Duerkop - Chief Executive Officer, Novasign
Continuous improvement methodology has been employed for many years to improve manufacturing where effectiveness depends on team experience. Advanced modeling technology for biomanufacturing promises to make continuous improvement methodology more widespread and allow teams to achieve expert results with far less experience. This presentation will illustrate model based continuous improvement across a drug substance biomanufacturing process using an industrial case study.
- Joseph Pekny - Professor, Chemical Engineering, Purdue University
- Yiwei Zhao - Director, Analytical Development, Mural Oncology
- Nadine Ritter, Ph.D. - President and Analytical Advisor, Global Biotech Experts, LLC
- Ramani Raghavan - Vice President, Mersana Therapeutics
- Monica Sadek - Technical Development Scientist 2, Protein Analytical Chemistry, Genentech
This presentation delves into the evolving landscape of supply chain management for CGTs, offering insights into the latest developments that are reshaping the industry. The session begins with an overview of traditional supply chain practices, highlighting their limitations and the pressing need for adaptation in an ever-changing global market. From there, it transitions into an exploration of cutting-edge innovations such as artificial intelligence (AI), machine learning, blockchain technology, and Internet of Things (IoT). These technologies are revolutionizing supply chain processes, enhancing efficiency, visibility, and responsiveness across the entire network. We will also consider predictive analytics to digital twins and autonomous systems, which can empower organizations to anticipate disruptions, optimize inventory management, and streamline operations for maximum effectiveness. In addition, we will consider sustainability initiatives, circular economy practices, agile supply chains, and the integration of advanced robotics and automation. By offering a comprehensive overview of these innovations, tools, and trends, attendees will be equipped with the knowledge and insights necessary to navigate the complexities of modern supply chain management.
- Jared Auclair, PhD - Vice Provost Research Economic Development, Director of Bioinnovation, College of Science at Northeastern University
Many pharma and biotech companies onboarded thousands of materials and increased inventory during the pandemic. With the endemic in full swing, organizations have a surplus of material that is about to or has already expired. This presentation seeks to explain how the presenter worked to extend the shelf life of various materials for continuity improvement and financial savings.
- Michelle Parziale - Senior Engineer - MS&T, Moderna
- Scalable methods to optimize EV Isolation & Purification
- Efficient techniques for manipulating EV properties (size, surface ligands, cargo loading etc.) for enhanced targeting and in vivo delivery
- Challenges and potential strategies for adhering to strict GMP regulations for clinical-grade EV production.
- Christopher Locher - CEO & Co-Founder, Versatope, USA
- Gargi Roy M.Sc. - Associate Director, BioPharmaceuticals Development, AstraZeneca
- Parameswari Govindarajan, PhD - Senior Scientist, CSL Behring
- Kalle Johnson - Senior Director, UPSIDE Foods
- Brian Gregory Youchak - Sr. Advisor, Eli Lilly and Company
- Andrew Zydney, Ph.D. - Bayard D. Kunkle Chair, Chemical Engineering, Penn State University
- Stefano Menegatti - Associate Professor, North Carolina State University
- Ohnmar Khanal, Ph.D - Downstream Technology Lead, Spark Therapeutics
- How do we define AI/ML?
- Which industries have already implemented AI/ML? How can the Biopharma industry learn from this?
- Is Biopharma prepared for this transition?
- Early adopter’s vs late adopters: Will there be any impact?
- How can small, mid-size, and large companies strategize for ML/AI implementation?
- Can it be beneficial for all areas of biopharmaceutical development (discovery, development, clinical and manufacturing)
- Cost reduction and accelerated timelines for project
- Amish Patel - SVP, Technical Activity Operations, Calidi Biotherapeutics
- Trisha Tucholski - Program Officer, Board on Life Sciences, National Academies
- Lili Wang - Fellow, National Institute of Standards and Technology
- Lisa Pieri - Scientist, Ultragenyx
- Trisha Tucholski - Program Officer, Board on Life Sciences, National Academies
- Lili Wang - Fellow, National Institute of Standards and Technology
- Lisa Pieri - Scientist, Ultragenyx
- Navigating diverse region-specific frameworks to expedite approvals.
- Build strategic partnerships with local distributors to facilitate market entry.
- Tailor marketing and patient education strategies
- Collaborating with local health services/distributors in preparation for product launch
- Ensuring preparedness for your supply/logistics chain across goal market
- E.g. Cryopreservation facility/availability when transporting
- Amish Patel - SVP, Technical Activity Operations, Calidi Biotherapeutics
- Ben Doak - Head of Innovative Treatments, NHS England
- Nathan Lee - Senior Director, Gene Therapy CMC, Poseida Therapeutics
- Shashi Murthy, PhD - CTO and Co-Founder, Nanite Inc.